A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jan 23

PMID 38254823

Authors

Dixita M Patel

Ruba Mateen

Noor Qaddour

Alessandra Carrillo

Claire Verschraegen

Yuanquan Yang

Zihai Li

Debasish Sundi

Amir Mortazavi

Katharine A Collier

Affiliations

Soon will be listed here.

Abstract

Urothelial cancer is an immune-responsive cancer, but only a subset of patients benefits from immune checkpoint inhibition. Currently, single-agent immune checkpoint inhibitors (ICIs) and the combination of pembrolizumab with the antibody-drug conjugate enfortumab vedotin are approved to treat patients with metastatic UC (mUC). Approval of first-line nivolumab in combination with gemcitabine and cisplatin is expected imminently. Many treatment approaches are being investigated to better harness the immune system to fight mUC. In this review, we summarize the landmark clinical trials of ICIs that led to their incorporation into the current standard of care for mUC. We further discuss recent and ongoing clinical trials in mUC, which are investigating ICIs in combination with other agents, including chemotherapy, antibody-drug conjugates, tyrosine kinase inhibitors, and novel antibodies. Lastly, we review novel approaches utilizing bispecific antibodies, cellular therapies, and vaccines. The landscape of immunotherapy for mUC is rapidly evolving and will hopefully lead to better outcomes for patients.

Citing Articles

FGFR-Altered Urothelial Carcinoma: Resistance Mechanisms and Therapeutic Strategies.

Benjamin D, Mita A Target Oncol. 2024; 20(1):1-11.

PMID: 39690380 DOI: 10.1007/s11523-024-01119-z.

Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives.

Kwon W, Lee M Cancers (Basel). 2024; 16(23).

PMID: 39682263 PMC: 11640162. DOI: 10.3390/cancers16234078.

Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer.

Taylor C, Patterson K, Friedman D, Bacot S, Feldman G, Wang T Cancers (Basel). 2024; 16(17).

PMID: 39272928 PMC: 11393896. DOI: 10.3390/cancers16173071.

Identification of a circadian-based prognostic signature predicting cancer-associated fibroblasts infiltration and immunotherapy response in bladder cancer.

Zhou L, He J, Hu Z, Li H, Li J Aging (Albany NY). 2024; 16(17):12312-12334.

PMID: 39216004 PMC: 11424586. DOI: 10.18632/aging.206088.

References

Matsumoto K, Noguchi M, Satoh T, Tabata K, Fujita T, Iwamura M . A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int. 2010; 108(6):831-8. DOI: 10.1111/j.1464-410X.2010.09933.x. View

Apolo A, Ellerton J, Infante J, Agrawal M, Gordon M, Aljumaily R . Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer. 2020; 8(2). PMC: 7549450. DOI: 10.1136/jitc-2020-001246. View

Sweeney C, Roth B, Kabbinavar F, Vaughn D, Arning M, Curiel R . Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006; 24(21):3451-7. DOI: 10.1200/JCO.2005.03.6699. View

Balar A, Kamat A, Kulkarni G, Uchio E, Boormans J, Roumiguie M . Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021; 22(7):919-930. DOI: 10.1016/S1470-2045(21)00147-9. View

Qu Y, Sun Z, Han W, Zou Q, Xing N, Luo H . Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study. J Immunother Cancer. 2022; 10(5). PMC: 9092172. DOI: 10.1136/jitc-2021-004427. View

Galsky M, Wang H, Hahn N, Twardowski P, Pal S, Albany C . Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. Eur Urol. 2017; 73(5):751-759. DOI: 10.1016/j.eururo.2017.12.001. View

McCaffrey J, Hilton S, Mazumdar M, Sadan S, Kelly W, Scher H . Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997; 15(5):1853-7. DOI: 10.1200/JCO.1997.15.5.1853. View

Modi S, Saura C, Yamashita T, Park Y, Kim S, Tamura K . Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2019; 382(7):610-621. PMC: 7458671. DOI: 10.1056/NEJMoa1914510. View

Powles T, Park S, Caserta C, Valderrama B, Gurney H, Ullen A . Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. J Clin Oncol. 2023; 41(19):3486-3492. PMC: 10306435. DOI: 10.1200/JCO.22.01792. View

10.

Oudard S, Culine S, Vano Y, Goldwasser F, Theodore C, Nguyen T . Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. Eur J Cancer. 2014; 51(1):45-54. DOI: 10.1016/j.ejca.2014.10.009. View

11.

Powles T, van der Heijden M, Castellano D, Galsky M, Loriot Y, Petrylak D . Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020; 21(12):1574-1588. DOI: 10.1016/S1470-2045(20)30541-6. View

12.

Noguchi M, Matsumoto K, Uemura H, Arai G, Eto M, Naito S . An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy. Clin Cancer Res. 2015; 22(1):54-60. DOI: 10.1158/1078-0432.CCR-15-1265. View

13.

Ott P, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N . A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020; 183(2):347-362.e24. DOI: 10.1016/j.cell.2020.08.053. View

14.

Tang B, Xiao J, Chi Z, Duan R, Cui C, Si L . Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma. Oncologist. 2024; 30(2). PMC: 11883152. DOI: 10.1093/oncolo/oyae260. View

15.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

16.

Massard C, Gordon M, Sharma S, Rafii S, Wainberg Z, Luke J . Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016; 34(26):3119-25. PMC: 5569690. DOI: 10.1200/JCO.2016.67.9761. View

17.

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View

18.

ODonnell P, Milowsky M, Petrylak D, Hoimes C, Flaig T, Mar N . Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023; 41(25):4107-4117. PMC: 10852367. DOI: 10.1200/JCO.22.02887. View

19.

Robbins P, Kassim S, Tran T, Crystal J, Morgan R, Feldman S . A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2014; 21(5):1019-27. PMC: 4361810. DOI: 10.1158/1078-0432.CCR-14-2708. View

20.

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J . Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18(3):312-322. DOI: 10.1016/S1470-2045(17)30065-7. View